All posts in BPS News

The Boulder Peptide Society will host its 9th Annual meeting in Boulder, CO on September 28 to October 1, 2015.  The Boulder Peptide Symposium once again brings together thought leaders in biotech, pharma, and academic institutions to present current paradigms in peptide therapeutics and to uncover solutions to challenges in peptide drug discovery and development. BPS is pleased to offer a preview of this year's program.

Richard DiMarchi, Ph.D. the Standiford H. Cox Distinguished Professor of Chemistry and the Linda & Jack Gill Chair in Biomolecular Sciences at Indiana University has been named as the 2015 recipient of the Meienhofer Award for Excellence in Peptide Sciences. The award will be presented to Dr. DiMarchi on September 30, 2015 at the Boulder Peptide Symposium, which will take place from September 28 to October 1, 2015 in Boulder, Colorado, where Dr. DiMarchi will give a presentation of highlights from his prodigious record of research achievements.

Dr. DiMarchi's contributions in peptide & protein sciences consist of three decades of work in academia, the pharmaceutical industry and biotechnology companies. He is a co-founder of Ambrx, Inc., Marcadia Biotech, Assembly, Calibrium and MB2 Biotech. He has served as a scientific advisor to multiple pharmaceutical companies (Kai, Ferring, Lilly, Merck, and Roche), three venture funds; 5AM, TMP, Twilight and a former board member of BIO, Isis and Millenium-Bio. He is currently Chairman of the Peptide Therapeutics Foundation and external board member at Assembly Biosciences and On-Target Therapeutics.

Dr. DiMarchi earned his Ph.D. from Indiana University in 1979.  He completed post-doctoral training at Rockefeller University under the mentorship of Noble Laureate Prof. Bruce Merrifield after which he began a twenty-two year career as a scientist and executive at Eli Lilly and Company. For more than two decades at Lilly Research Laboratories he provided leadership in biotechnology, endocrine research and product development, retiring as Group Vice President in 2003. The focus of much of Dr. DiMarchi’s research has been the chemical biology of endocrine hormones, and more specifically those pertaining to diabetes and obesity.  He is readily recognized for discovery and development of rDNA derived Humalog® (LisPro-human insulin) and the advancement of mixed incretin agonists for treatment of the metabolic syndrome. As scientist and executive, Dr. DiMarchi also significantly contributed to the commercial development of Humulin®, Humatrope®, rGlucagon®, Evista®, and Forteo®. His current research is focused on developing macromolecules with enhanced therapeutic properties through biochemical and chemical optimization, an approach he has termed chemical-biotechnology. He is the author of nearly two hundred scientific publications and holds more than a hundred patents.

Dr. DiMarchi is the recipient of numerous awards including the 2005 AAPS Career Research Achievement Award in Biotechnology, the 2006 ACS Barnes Award for Leadership in Chemical Research Management, the 2006 ACS Esselen Award for Chemistry in the Service of Public Interest, the 2007 Carothers Award for Excellence in Polymer Sciences, the 2009 Watanabe Award for Life Sciences Research, the 2011 Merrifield Award for Career Contributions in Peptide Sciences, the 2012 Phillip Nelson Innovation Award, the 2014 Erwin Schrödinger-Preis, a 2014 inductee to the National Inventors Hall of Fame, a 2015 winner of the Patient Advocacy award of the philanthropic society Cures within Reach, a 2015 inductee to the National Association of Inventors.

More information on the Meienhofer Award, including a list of previous recipients, and the Boulder Peptide Symposium can be found online at www.boulderpeptide.org.

May 11, 2015 - Boulder, Colorado

The Boulder Peptide Society will host its 9th Annual meeting in Boulder, CO on September 28 to October 1, 2015. Discounted early registration is available until May 31 on the BPS website at:

Boulder Peptide Symposium 2015 Registration

The Boulder Peptide Symposium once again brings together thought leaders in biotech, pharma, and academic institutions to present current paradigms in peptide therapeutics and to uncover solutions to challenges in peptide drug discovery and development. BPS is pleased to offer a preview of this year's program.

Scientific Sessions: Chemistry and Analytics

Synthesis and bioactivity of glycopeptides and peptide-protein conjugates, Thomas Tolbert, Associate Professor, The University of Kansas

Macrocyclic Organo-Peptide Hybrids as Molecular Scaffolds for Targeting Protein-Protein Interactions, Rudy Fasan, Associate Professor, University of Rochester

Engineering Potent and Selective Analogues of GpTx-1, a Tarantula Venom Peptide Antagonist of the NaV1.7 Sodium Channel, Les Miranda, Director Research, Therapeutic Discovery, Amgen Inc.

Cell-penetrating peptides: current landscape & future applications, Francesca Milletti, Principal Scientist, Roche

Scientific Sessions: Peptides in the Clinic

Injecting Hope: Clinical Development of the NeuVax Vaccine, Elizabeth Mittendorf, Associate Professor, Deputy Chair Research, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center

The Clinical Development of Peixganan for the Treatment of Diabetic Foot Infections, Warren Joseph, Consultant, Lower Extremity Infectious Diseasess, Roxborough Memorial Hospital, Philadelphia, PA

Clinical efficacy of a novel P-15 peptide in anterior cervical arthrodesis: A prospective, randomized, controlled, multicenter study, Jerome Connor, Vice President of Research and Development, Cerapedics Inc.

First in class anti-infectives from a novel cationic peptide platform, Deborah O'Neil, Chief Executive & Scientific Officer, NovaBiotics Ltd.

The Clinical Development of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Extensive-stage Small Cell Lung Cancer (SCLC) and Metastatic Renal Cell Carcinoma (mRCC), John R. Stille, Senior Clinical Research Advisor, Eli Lilly and Company

Scientific Sessions: Drug Delivery and Formulations

MICROCOR®: A novel platform transdermal technology for convenient and effective delivery of peptides, Bobby Singh, CTO, Corium International, Inc.

A Chemical Approach to Half-life Extension of Peptides and Proteins, Daniel Santi, President, ProLynx

ELP Biopolymers Significantly Enhance the Pharmacology of Therapeutic Peptides, Jim Ballance, VP Research & Scientific Affairs, PhaseBio Pharmaceuticals, Inc.

Development of a Topical Anti-inflammatory Cell Permeable Peptide for Uveitis, Bruce Littman, CEO, Portage Pharmaceuticals LTD

Peptide Showcase

M. Karen Newell-Rogers, Professor/Consultant, VG Life Sciences/Texas A&M Health Sciences Center

Robin Carmichael, President &COO, Helix BioMedix

Ken Cundy, Chief Scientific Officer, CohBar, Inc.

Michael Sekar, Sr. Director, Formulation Research, Durect Corporation

Andreas Rybka, Head of Chemistry, Nexigen GmbH

Nozer Mehta, Vice President, Biologics, MonoSol Rx

Pascal Deschatelets, Chief Operating Officer, Apellis Pharmaceuticals

Craig Beattie, Chief Scientific Officer, CDG Therapeutics

Jamal Temsamani, Director of Drug Development, Vect-Horus

Fa Liu, Director of Chemistry, Calibrium, LLC

If you wish to be considered for a presentation, please apply at the link:

http://www.boulderpeptide.org/apply-to-present

The 9th Annual meeting will take place at the beautiful St. Julien Hotel and Spa, which has been the venue for this meeting since it’s inception. Boulder Peptide Society is a nonprofit 501(c)(3) organization. More information about the mission of the society and the details of the meeting can be found on the website at www.boulderpeptide.org.

March 10, 2015 - Boulder, Colorado

The Boulder Peptide Society will host its 9th Annual meeting in Boulder, CO on September 28 to October 1, 2015.  The Boulder Peptide Symposium once again brings together thought leaders in biotech, pharma, and academic institutions to present current paradigms in peptide therapeutics and to uncover solutions to challenges in peptide drug discovery and development. BPS is pleased to offer a preview of this year's program.

Scientific Sessions:  Chemistry and Analytics

Synthesis and bioactivity of glycopeptides and peptide-protein conjugates, Thomas Tolbert, Associate Professor, The University of Kansas

Macrocyclic Organo-Peptide Hybrids as Molecular Scaffolds for Targeting Protein-Protein Interactions, Rudy Fasan, Associate Professor, University of RochesterS

Engineering Potent and Selective Analogues of GpTx-1, a Tarantula Venom Peptide Antagonist of the NaV1.7 Sodium Channel, Les Miranda, Director Research, Therapeutic Discovery, Amgen Inc.

Cell-penetrating peptides: current landscape & future applications, Francesca Milletti, Principal Scientist, Roche

Scientific Sessions:  Peptides in the Clinic

Injecting Hope: Clinical Development of the NeuVax Vaccine, Elizabeth Mittendorf, Associate Professor, Deputy Chair Research, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center

The Clinical Development of Peixganan for the Treatment of Diabetic Foot Infections, Warren Joseph, Consultant, Lower Extremity Infectious Diseasess, Roxborough Memorial Hospital, Philadelphia, PA

Clinical efficacy of a novel P-15 peptide in anterior cervical arthrodesis: A prospective, randomized, controlled, multicenter study, Jerome Connor, Vice President of Research and Development, Cerapedics Inc.

First in class anti-infectives from a novel cationic peptide platform, Deborah O'Neil, Chief Executive & Scientific Officer, NovaBiotics Ltd.

The Clinical Development of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Extensive-stage Small Cell Lung Cancer (SCLC) and Metastatic Renal Cell Carcinoma (mRCC), John R. Stille, Senior Clinical Research Advisor, Eli Lilly and Company

Scientific Sessions:  Drug Delivery and Formulations

MICROCOR®: A novel platform transdermal technology for convenient and effective delivery of peptides, Bobby Singh, CTO, Corium International, Inc.

A Chemical Approach to Half-life Extension of Peptides and Proteins, Daniel Santi, President, ProLynx

ELP Biopolymers Significantly Enhance the Pharmacology of Therapeutic Peptides, Jim Ballance, VP Research & Scientific Affairs, PhaseBio Pharmaceuticals, Inc.

Development of a Topical Anti-inflammatory Cell Permeable Peptide for Uveitis, Bruce Littman, CEO, Portage Pharmaceuticals LTD

Peptide Showcase

M. Karen Newell-Rogers, Professor/Consultant, VG Life Sciences/Texas A&M Health Sciences Center

Robin Carmichael, President &COO, Helix BioMedix

Ken Cundy, Chief Scientific Officer, CohBar, Inc.

Michael Sekar, Sr. Director, Formulation Research, Durect Corporation

Andreas Rybka, Head of Chemistry, Nexigen GmbH

Nozer Mehta, Vice President, Biologics, MonoSol Rx

Pascal Deschatelets, Chief Operating Officer, Apellis Pharmaceuticals

Craig Beattie, Chief Scientific Officer, CDG Therapeutics

Jamal Temsamani, Director of Drug Development, Vect-Horus

Fa Liu, Director of Chemistry, Calibrium, LLC

If you wish to be considered for a presentation, please apply at the link:

http://www.boulderpeptide.org/apply-to-present

The 9th Annual meeting will take place at the beautiful St. Julien Hotel and Spa, which has been the venue for this meeting since it’s inception. Boulder Peptide Society is a nonprofit 501(c)(3) organization. Moreinformation about the mission of the society and the details of the meeting can be found on the website at www.boulderpeptide.org.

Boulder, CO, February 25, 2015

The Boulder Peptide Society will host its 9th Annual meeting in Boulder, CO on September 28 to October 1, 2015.

In preparation, the Society Board of Directors has assembled an esteemed Scientific Advisory Board with significant industry and academic experience in discovery and development of peptide therapeutics. The SAB is responsible for identifying, soliciting, and reviewing speakers for the scientific sessions, business showcase, Meienhofer and Young Investigator Awards, posters, and for editing the newsletter. We thank the 2015 SAB members below for volunteering their time to make the meeting a success.

•  Hubert Chen, MD, Peptides in the Clinic
•  Waleed Danho, PhD, Chemistry and Analytical
•  David Litzinger, PhD, Formulation and Delivery
•  James Matriano, PhD, Business Showcase
•  Nader Fatouhi, PhD, Meienhofer Award
•  Phil Dawson, PhD, Young Investigator Award
• John Mayer, PhD, Newsletter Editor
•  Richard DiMarchi, PhD, Industry-Academic Partnerships Panel

If you wish to be considered for a presentation, please apply at the link:

http://www.boulderpeptide.org/apply-to-present

The 9th Annual meeting will take place at the beautiful St. Julien Hotel and Spa, which has been the venue for this meeting since it’s inception. Boulder Peptide Society is a nonprofit 501(c)(3) organization. Moreinformation about the mission of the society and the details of the meeting can be found on the website at www.boulderpeptide.org.

Boulder, CO, January 20, 2015 -- The Boulder Peptide Society will host its 9th Annual meeting in late September 2015 in Boulder, Colorado. In preparation, the society has issued a call for abstracts for the three core scientific sessions of the meeting:

Scientific Session 1: Peptides in the Clinic

Oral presentations on peptide therapeutics in clinical development with an emphasis on human clinical data in Phase II or beyond.

Scientific Session 2:  Drug Delivery

Novel approaches to peptide drug delivery including devices, molecular engineering, conjugation, and formulation technologies

Scientific Session 3:  Chemistry and Analytics

Novel peptide synthesis, conjugation, and side-chain modification chemistries along with advanced analytical techniques applicable to peptide therapeutics will be presented.

Apply now on our website.

ABOUT THE BOULDER PEPTIDE SYMPOSIUM

The 2015 Boulder Peptide Symposium once again brings together thought leaders in biotech, pharma, and academic institutions to present current paradigms in peptide therapeutics and to uncover solutions to challenges in peptide drug discovery and development.

The Boulder Peptide Symposium is a nonprofit organization. More information about the mission and the annual meeting can be found on the website at www.boulderpeptide.org.

The Scientific Advisory Board of the Boulder Peptide Society is pleased to add William Lambert, Ph.D. to help craft the scientific session of the 2014 Boulder Peptide Symposium.

Bill brings a wealth of pharmaceutical development leadership experience through
the formulation and delivery technology roles he has held at both pharmaceutical and delivery companies such as Pfizer, Eisai, and Pacira Pharmaceuticals.  He is currently Fellow and Head of the Innovative Drug Delivery Group at MedImmune / AstraZeneca in Gaithersburg, MD.  Bill has a Ph.D. From the University of Utah.

Welcome to our team Bill !